Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. develops clinical-stage biotechnology programs centered on PAS-004, a next-generation macrocyclic MEK inhibitor. Company news for KTTAW, the Nasdaq-listed warrants to purchase Pasithea common stock, typically covers PAS-004 clinical and regulatory updates in neurofibromatosis type 1-associated plexiform neurofibromas, MAPK pathway-driven advanced solid tumors, ALS, and other disease areas tied to RASopathies and CNS disorders.
Recurring developments include FDA designations, clinical pharmacokinetic, pharmacodynamic, safety, and tolerability data, research grants, healthcare conference presentations, and capital actions such as public equity offerings. The coverage also reflects Pasithea's status as a public biotechnology issuer with common stock and warrants listed on The Nasdaq Capital Market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.